Trasylol (aprotinin) as an anti-tumour agent.


Growth of a syngeneic adenocarcinoma in C3H mice was investigated in animals receiving twice-daily subcutaneous injections of the antiprotease Trasylol. Development of primary tumours was not influenced by Trasylol treatment and the antiprotease did not affect concomitant ant--tumour immunity as assessed by resistance to secondary footpad challenge. From… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics